NCT03457532: A Phase I Study of SCC244

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MET
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult), Senior)
Location of Metastases: 
Additional Notes: Patients must have c-MET alteration (amplification, over-expression or c-MET axon 14 skipping)

Comments are closed.

Up ↑